Stockreport

Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Neumora Therapeutics, Inc.  (NMRA) 
PDF New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies  KOASTAL-2 and -3 fully enro [Read more]